CP
PHAT icon

Catalys Pacific’s Phathom Pharmaceuticals PHAT Stock Holding History

Catalys Pacific’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.6M Buy
1,493,854
+64,840
+5% +$819K 7.19% 2
2025
Q4 		$23.7M Buy
1,429,014
+261,900
+22% +$3.74M 7.63% 2
2025
Q3 		$13.7M Hold
1,167,114
– – 3.91% 2
2025
Q2 		$11.2M Hold
1,167,114
– – 8.5% 2
2025
Q1 		$7.32M Hold
1,167,114
– – 4.92% 2
2024
Q4 		$9.48M Buy
1,167,114
+44,542
+4% +$552K 8.18% 2
2024
Q3 		$20.3M Buy
1,122,572
+400,610
+55% +$5.6M 16.19% 2
2024
Q2 		$7.44M Hold
721,962
– – 5.61% 3
2024
Q1 		$7.67M Hold
721,962
– – 5.18% 3
2023
Q4 		$6.59M Buy
+721,962
New +$6.22M 6.18% 3

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $653B AUM 32.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return